{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:59:51Z","timestamp":1793771991785,"version":"4.6.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mutations in splicing factor (SF) genes\u00a0SRSF2, U2AF1, SF3B1,\u00a0and\u00a0ZRSR2\u00a0are now considered adverse risk in the European LeukemiaNet 2022 acute myeloid leukemia (AML) risk stratification. The prognostic impact of SF mutations in AML has been predominantly derived from younger patients treated with intensive (INT) therapy. We evaluated 994 patients with newly diagnosed AML, including 266 (27%) with a SFmut. Median age was 67 years overall, with patients with SFmut\u00a0being older at 72 years.\u00a0SRSF2\u00a0(n\u00a0= 140, 53%) was the most common SFmut. In patients treated with INT, median relapse-free survival (RFS) (9.6 vs 21.4 months,\u00a0P\u00a0= .04) and overall survival (OS) (15.9 vs 26.7 months,\u00a0P\u00a0= .06) were shorter for\u00a0patients with\u00a0SFmut\u00a0than\u00a0without SFwt,\u00a0however this significance abrogated when evaluating patients who received venetoclax with INT therapy (RFS 15.4 vs 20.3 months,\u00a0P\u00a0= .36; OS 19.6 vs 30.7 months,\u00a0P\u00a0= .98). In patients treated with LI, median RFS (9.3 vs 7.7 months,\u00a0P\u00a0= .35) and OS (12.3 vs 8.5 months,\u00a0P\u00a0= .14) were similar for patients with and without\u00a0SFmut\u00a0, and outcomes improved in all groups with venetoclax. On multivariate analysis, SFmut\u00a0did not affect hazards of relapse and death for INT arm but reduced both these hazards in LI arm. In a large AML data set with &amp;gt;60% of patients receiving venetoclax with LI\/INT therapy, SFmut\u00a0had no independent negative\u00a0prognostic impact. Newer prognostic models that consider LI therapy and use of venetoclax among other factors are warranted.<\/jats:p>","DOI":"10.1182\/blood.2023020649","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T17:57:51Z","timestamp":1689271071000},"page":"1647-1657","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":72,"title":["Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-2567","authenticated-orcid":false,"given":"Jayastu","family":"Senapati","sequence":"first","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Urrutia","sequence":"additional","affiliation":[{"name":"2Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[{"name":"3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-3562","authenticated-orcid":false,"given":"Hussein A.","family":"Abbas","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-1613","authenticated-orcid":false,"given":"Kelly S.","family":"Chien","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle E.","family":"Hammond","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-2427","authenticated-orcid":false,"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[{"name":"3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2023110916245186700_bib1","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood-2016-10-692400","article-title":"Splicing factor gene mutations in hematologic malignancies","volume":"129","author":"Saez","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023110916245186700_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13073-015-0226-3","article-title":"The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical\u2013genomic driver associations","volume":"7","author":"Lee","year":"2015","journal-title":"Genome Med"},{"issue":"15","key":"2023110916245186700_bib3","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023110916245186700_bib4","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","article-title":"Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations","volume":"132","author":"Pellagatti","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2023110916245186700_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s41375-023-01899-9","article-title":"Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations","volume":"37","author":"Urrutia","year":"2023","journal-title":"Leukemia"},{"issue":"23","key":"2023110916245186700_bib6","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023110916245186700_bib7","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"2023110916245186700_bib8","doi-asserted-by":"crossref","first-page":"9084","DOI":"10.18632\/oncotarget.7000","article-title":"Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia","volume":"7","author":"Hou","year":"2016","journal-title":"Oncotarget"},{"issue":"17","key":"2023110916245186700_bib9","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1182\/bloodadvances.2021004556","article-title":"Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification","volume":"5","author":"van der Werf","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2023110916245186700_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023110916245186700_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2023110916245186700_bib12","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2023110916245186700_bib13","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","article-title":"Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax","volume":"5","author":"Lachowiez","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2023110916245186700_bib14","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"2023110916245186700_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2023110916245186700_bib16","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","article-title":"Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study","volume":"9","author":"Lachowiez","year":"2022","journal-title":"Lancet Haematol"},{"issue":"9","key":"2023110916245186700_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"2023110916245186700_bib18","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1182\/blood-2022-157603","article-title":"Outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era of myeloid therapies","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2023110916245186700_bib19","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1080\/10428194.2022.2095629","article-title":"Impact of SF3B1 mutation in myelofibrosis","volume":"63","author":"Senapati","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023110916245186700_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"2023110916245186700_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41591-022-01696-4","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","volume":"28","author":"Ganan-Gomez","year":"2022","journal-title":"Nat Med"},{"issue":"23","key":"2023110916245186700_bib22","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.21.00067","article-title":"Optimizing risk stratification in acute myeloid leukemia: dynamic models for a dynamic therapeutic landscape","volume":"39","author":"Short","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023110916245186700_bib23","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023020649\/2088490\/blood_bld-2023-020649-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023020649\/2088490\/blood_bld-2023-020649-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T11:25:13Z","timestamp":1699529113000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/19\/1647\/496862\/Venetoclax-abrogates-the-prognostic-impact-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":23,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,11,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020649","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}